Aims of the meeting: To assess current understanding of hepatitis B virus (HBV), the disease that it causes, and its optimal management; and to make recommendations for directions for future research, both basic and clinical. Topics will include HBV replication and mode of inducing chronicity, the immunology of hepatitis B, the virus-host interactions, the natural history of chronic infection, and up-to-date results of trials of antiviral therapies including peginterferon, lamivudine, adefovir dipivoxil, tenofovir, entecavir, emtricitabine, and telbivudine alone and in combination. Histological, clinical and virological endpoints of therapy and the needs for future research will be discussed. The meeting will be sponsored by the Liver Disease Research Branch of the Division of Digestive Diseases and Nutrition of NIDDK in collaboration with the American Association for the Study of Liver Disease (AASLD). A summary of the meeting and these recommendations would be submitted for publication.     Sponsored By National Institute of Diabetes and Digestive and Kidney Diseases American Association for the Study of Liver Diseases Hepatitis B Foundation Hepatitis Foundation International     Organizers Edward Doo (NIDDK) Russell Fleischer (FDA) Jay H. Hoofnagle (NIDDK) T. Jake Liang (NIDDK) Anna Lok (University of Michigan) John Vierling (Baylor College of Medicine)     If you have any logistical questions or are experiencing difficulty with the registration process, please contact Sandy Lebowitz at slebowitz@scgcorp.com or at (301) 670-4990.

Return to NIDDK homepage. This page last updated: 1/11/2006